KRAS and lung carcinoma: Then, we tested DKK2 blockade in a mouse lung cancer model of carrying an activating Kras mutation and loss of Apc. Treatment of these mice with anti-DKK2 antibody significantly reduced tumor number and tumor size (Fig. 7a–c), and enhanced activation of NK cells in both of tumor draining lymphoid node and tumor tissues (Fig. 7f, g).